Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/20/2025 | $60.00 | Buy | Canaccord Genuity |
| 5/16/2025 | $62.00 | Buy | BTIG Research |
| 5/14/2025 | $48.00 | Hold → Buy | Needham |
| 4/14/2025 | Hold | Needham | |
| 5/22/2024 | $60.00 | Buy → Neutral | Citigroup |
| 8/31/2023 | $75.00 | Overweight | JP Morgan |
| 6/29/2023 | $79.00 | Buy | Citigroup |
| 10/14/2022 | $90.00 | Overweight | Stephens |
S-8 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
10-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that it has surpassed more than five million Motiva devices in market. This milestone underscores the company's long‑standing commitment to science‑based innovation and reflects sustained global adoption of Motiva's portfolio of breast aesthetics and reconstruction solutions across more than 100 countries worldwide. "Surpassing five million Motiva devices is another milestone for our company, and a clear reflection that our investment in bringing better technology and procedures to mar
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced a strategic leadership transition of Raj Denhoy, current Chief Financial Officer to Senior Vice President, Global Strategy, and the appointment of Cassandra "Sandra" Harris to Senior Vice President and Chief Financial Officer, effective March 9, 2026. "Over the past few years, we have been focused on driving efficient execution and scalability. With the company well positioned for its next chapter of growth, we are creating additional leadership capacity to maintain operational momentum
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided 2026 guidance. Fourth Quarter Highlights and Outlook Fourth quarter revenue of $64.6 million, an increase of 45.2% from the year-ago period. 2025 revenue of $211.1 million, an increase of 27.2% over 2024. Motiva U.S. revenue in the fourth quarter of $17.3 million, and full year U.S. revenue of $45.6 million. Fourth quarter net loss from operations of $3.9 million, a 79% reduction compa
Canaccord Genuity initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $60.00
BTIG Research initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $62.00
Needham upgraded Establishment Labs from Hold to Buy and set a new price target of $48.00
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided 2026 guidance. Fourth Quarter Highlights and Outlook Fourth quarter revenue of $64.6 million, an increase of 45.2% from the year-ago period. 2025 revenue of $211.1 million, an increase of 27.2% over 2024. Motiva U.S. revenue in the fourth quarter of $17.3 million, and full year U.S. revenue of $45.6 million. Fourth quarter net loss from operations of $3.9 million, a 79% reduction compa
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2025, before the market opens on Tuesday, February 24, 2026, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13758679. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the third quarter ended September 30, 2025. Third Quarter Highlights and Outlook (Unaudited) Third quarter worldwide revenue of $53.8 million, an increase of 33.8% from the year ago period. Revenue included $11.9 million of Motiva sales in the United States. 2025 revenue expected to exceed $210 million, an increase from previous guidance of $208 million to $212 million. Third quarter gross margin of 70.1% compared to 63.9% in the year-ago period and 68.8% in th
SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced a strategic leadership transition of Raj Denhoy, current Chief Financial Officer to Senior Vice President, Global Strategy, and the appointment of Cassandra "Sandra" Harris to Senior Vice President and Chief Financial Officer, effective March 9, 2026. "Over the past few years, we have been focused on driving efficient execution and scalability. With the company well positioned for its next chapter of growth, we are creating additional leadership capacity to maintain operational momentum
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced publication of its 2025 Post-Market Surveillance (PMS) Report. The report is being released ahead of the annual meeting of the American Society of Plastic Surgeons held October 9-12 in New Orleans. "Publishing our PMS report every year since the launch of Motiva in 2010 shows our dedication to accountability and transparency," said Peter Caldini, Establishment Labs Chief Executive Officer. "No other company in our industry publishes this level of information on an annual basis, and I would enc
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Peter Caldini as Chief Executive Officer effective May 7, 2025. Mr. Caldini has served as Interim CEO since March 1, 2025, when Establishment Labs' Founder and previous CEO Juan José Chacón-Quirós retired from the role. "After an extensive search process, it was clear that with his deep operational, commercial, and financial skills, Peter is the ideal person to lead Establishment Labs," commented Nick Lewin, Chairman of the Board of Establishment Labs. "We have a vision